Patient Education · Medical Weight Loss
What is retatrutide? The triple agonist, explained
Retatrutide is the most talked-about investigational weight loss medication in the world right now, and most of what patients read about it online is marketing. Here is the honest version from a medical weight loss provider: what it is, what the trials actually showed, and what it means for your options today.
Not FDA approved. Retatrutide is an investigational medication. This page is educational only.
One injection, three metabolic pathways.
Retatrutide is an investigational once-weekly injectable developed by Eli Lilly. Where semaglutide activates one receptor (GLP-1) and tirzepatide activates two (GLP-1 and GIP), retatrutide activates three: GLP-1, GIP, and glucagon. The glucagon pathway is the newcomer, and it appears to add meaningful energy expenditure on top of the appetite regulation the other two provide. In Phase 3 results reported in 2026, average weight loss reached approximately 28 percent of body weight at 80 weeks at the highest studied doses, the largest figure ever reported for an anti-obesity medication. An FDA decision is widely anticipated in late 2026 or 2027.
Retatrutide vs tirzepatide vs semaglutide, in one table.
| Semaglutide | Tirzepatide | Retatrutide | |
|---|---|---|---|
| Receptors activated | GLP-1 | GLP-1 + GIP | GLP-1 + GIP + glucagon |
| FDA status | Approved | Approved | Investigational; decision anticipated late 2026 or 2027 |
| Reported average weight loss in trials | Roughly 14 to 15 percent over 68 to 72 weeks | Roughly 20 percent over 72 weeks | Roughly 28 percent at 80 weeks (Phase 3, highest doses) |
| Dosing | Once weekly | Once weekly | Once weekly (investigational) |
| Available through a licensed provider today | Yes | Yes | Not as an approved treatment |
Trial figures come from different studies with different designs and populations; comparisons are approximate, not head-to-head. Individual results vary. Discuss expectations with a licensed provider.
About the retatrutide already for sale online.
Because the trial results are so striking, an entire gray market has appeared: websites selling retatrutide labeled for research use only, no prescription required. Be careful. These products are unapproved investigational substances. Their purity, dose accuracy, and sterility cannot be verified, and no licensed US pharmacy stands behind them. The FDA has repeatedly warned consumers about unapproved GLP-1 products sold online.
Vesta Aesthetics dispenses prescriptions exclusively through licensed 503A compounding pharmacies, with every protocol prescribed individually by Ali Claunch, NP-C after a personalized clinical evaluation. That standard is exactly why we publish pages like this one: informed patients make safer decisions, whatever they decide.
Should you wait for retatrutide, or start now?
For most patients, waiting one to two years for a possible approval rarely beats starting a medically supervised program now. FDA-approved pathways through semaglutide and tirzepatide already deliver substantial, well-studied results, and the metabolic benefits of starting earlier compound over time. Your plan can evolve as new medications are approved; your starting point does not lock you in.
Vesta provides provider-led medical weight loss by telehealth across Utah, Arizona, and Idaho. Care begins with a $75 initial consultation where Ali reviews your goals, history, and labs, then builds a personalized protocol around what is right for you today.
Retatrutide FAQs.
Curious what is right for you, today?
Skip the gray market. A $75 HIPAA compliant telehealth consultation with Ali Claunch, NP-C maps your options across Utah, Arizona, and Idaho.
Explore Medical Weight LossAvailability updates & treatment insights
Subscribe for availability updates, announcements, and treatment insights. For Utah, Arizona & Idaho patients, unsubscribe any time.
Deciding between medications? Semaglutide vs tirzepatide, compared →
Your plan starts with a $75 initial consultation
Meet one-on-one with Ali Claunch, NP-C through a HIPAA compliant telehealth consultation. We review your goals, health history, and labs, then build a personalized treatment plan. Caring for patients across Utah, Arizona, and Idaho, with in-clinic visits in Saratoga Springs.
Follow-up visits are included with an active membership. À la carte patients schedule a $75 follow-up consult at least every 90 days while on therapy.
Schedule a ConsultationA Note on Compounded Medications and FDA Oversight
Compounded peptides, GLP-1 medications, hormone therapies, NAD+ preparations, and other prescription items dispensed through Vesta Aesthetics are prepared by licensed 503A compounding pharmacies for individual patients pursuant to a valid prescription from Ali Claunch, NP-C, following a personalized clinical evaluation. Compounded medications are not FDA-approved. The FDA does not evaluate compounded preparations for safety, efficacy, or potency. Vesta Aesthetics operates in compliance with FDA regulations governing 503A patient-specific compounding and does not stock, resell, or distribute medications outside this framework. If the FDA changes guidance, restricts, or removes access to any compounded preparation, Vesta will discontinue that preparation in alignment with federal regulation.
Information on this site is educational and is not a substitute for individualized medical advice, diagnosis, or treatment. Outcomes vary by patient. No specific clinical result is promised or guaranteed. Use of any prescription medication carries risk; please review all risks with your provider before beginning therapy. Vesta Aesthetics is a self-pay medical practice and does not bill insurance. See our 503A Promise for full sourcing detail.